Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Net Margin (2019 - 2025)

Historic Net Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 151.4%.

  • BridgeBio Pharma's Net Margin rose 57797800.0% to 151.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 225.31%, marking a year-over-year decrease of 237900.0%. This contributed to the annual value of 241.44% for FY2024, which is 66724800.0% up from last year.
  • Per BridgeBio Pharma's latest filing, its Net Margin stood at 151.4% for Q3 2025, which was up 57797800.0% from 164.52% recorded in Q2 2025.
  • BridgeBio Pharma's Net Margin's 5-year high stood at 17732.17% during Q4 2021, with a 5-year trough of 40632.84% in Q3 2022.
  • Over the past 5 years, BridgeBio Pharma's median Net Margin value was 4506.12% (recorded in 2024), while the average stood at 6869.05%.
  • Within the past 5 years, the most significant YoY rise in BridgeBio Pharma's Net Margin was 1160772500bps (2021), while the steepest drop was -375890100bps (2021).
  • BridgeBio Pharma's Net Margin (Quarter) stood at 17732.17% in 2021, then tumbled by -141bps to 7357.81% in 2022, then crashed by -31bps to 9635.99% in 2023, then surged by 53bps to 4506.12% in 2024, then soared by 97bps to 151.4% in 2025.
  • Its last three reported values are 151.4% in Q3 2025, 164.52% for Q2 2025, and 143.55% during Q1 2025.